Dawid Studziński

Dawid Studziński

Auto-generated profile, based on publicly available information

Dawid Studziński

Municipal Hospital in Zabrze, Zamkowa 4, 41-803 Zabrze, Poland

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 February 2026 in Journal of Education, Health and Sport
Verified
Journal Article
Open access
AMAgnieszka Morawa
Agnieszka Morawa
KOKarolina Osińska
Karolina Osińska
MSMarcin Krzysztof Schulz
Marcin Krzysztof Schulz
MKMichał Kulczak
Michał Kulczak
DSDawid Studziński
Dawid Studziński
AKAnna Kołcz
Anna Kołcz
Introduction: Ankle sprains are a common injury affecting millions of people worldwide. While many cases are mild, they can lead to chronic joint instability, functional limitations and an increased risk of recurrence. Sprains most commonly involve the lateral ligaments of the joint, particularly ATFL, and in more complex cases, may also affect other structures, resulting in the high treatment costs. Aim: The aim of this article is to present modern methods of diagnosis, treatment and rehabilitation of ankle sprains, including innovative therapies and technologies that support recovery. Methods: A search of PubMed, Web of Science and Google Scholar was conducted. Included were randomized controlled trials, systematic review and meta-analyses of ankle sprain treatment and rehabilitation strategies. Results: An ankle sprain, if not treated properly, can lead to chronic instability, functional limitations and the risk of recurrence. Early diagnosis, intervention are crucial. Modern therapeutic methods such as micro-needle knives, electroacupuncture and rehabilitation robots offer promising treatment options. Integration of traditional methods with innovative technologies can speed up rehabilitation, improve joint stability and reduce the risk of recurrence. Conclusion: An ankle sprain, despite its initially mild nature,can lead to long term functional consequences. Early diagnosis and appropriate therapeutic intervention are crucial to minimise the risk of chronic instability and other complications. Modern diagnostic technologies and biological therapies are promising treatment options, accelerating the rehabilitation process and improving functional outcomes. However, these innovative methods require further research and verification of the reliability of the results obtained, as they are still in the early stages of development.

19 April 2026 in Quality in Sport
Verified
Journal Article
Open access
ATAlicja Trzepizur
Alicja Trzepizur
MSMonika Spaczyńska-Kwiatkowska
Monika Spaczyńska-Kwiatkowska
ZSZuzanna Socha
Zuzanna Socha
IOIzabela Ochońska
Izabela Ochońska
DSDawid Studziński
Dawid Studziński
JPJulia Pakulska
Julia Pakulska
Background: Hypoxic-ischemic encephalopathy (HIE) remains a major cause of neonatal mortality and long term neurodevelopmental impairment worldwide. Therapeutic hypothermia (TH) is currently the standard of care for newborns with moderate-to-severe HIE; however, several aspects of its use remain controversial. Aim: The aim of this paper is to present the current state of knowledge regarding the use of therapeutic hypothermia in newborns with HIE with particular emphasis on mechanisms of action, eligibility criteria, course of therapy, clinical efficacy and adverse effects, as well as to discuss current controversies and directions for further research. Material and methods: A narrative literature review was conducted using the PubMed database to identify studies on therapeutic hypothermia in newborns with hypoxic-ischemic encephalopathy. Publications from the past 11 years were included with particular emphasis on studies published within the last 5 years. Relevant original articles and review papers focusing on clinical outcomes and effectiveness were analyzed. Results: Therapeutic hypothermia reduces the risk of death and severe neurodevelopmental disability in newborns with moderate and severe HIE. Its neuroprotective effects are associated with reduced cerebral metabolism, decreased oxidative stress, modulation of inflammatory response, and inhibition of apoptosis. However, its efficacy in mild HIE and in preterm infants remains inconclusive. The most common adverse effects include cardiovascular, metabolic, and hematological disturbances requiring close monitoring. Conclusions: Therapeutic hypothermia is an effective and relatively safe treatment for HIE; however, it does not completely eliminate the risk of neurodevelopmental impairment. Further research is needed to optimize treatment protocols, expand its use to other populations and evaluate combination therapies.

15 May 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
KOKarolina Osińska
Karolina Osińska
AMAgnieszka Morawa
Agnieszka Morawa
MSMarcin Krzysztof Schulz
Marcin Krzysztof Schulz
DSDawid Studziński
Dawid Studziński
AKAnna Kołcz
Anna Kołcz
IOIzabela Ochońska
Izabela Ochońska
Introduction and Objective: The prevalence of maternal overweight and obesity has increased dramatically worldwide, posing significant risks for offspring health. Maternal obesity has been associated with multisystemic consequences, including metabolic, cardiovascular, neuroendocrine, renal, and immune disturbances. This review aims to synthesize current evidence on the impact of maternal obesity on offspring health and to identify potential mechanisms underlying these effects. Methods: A comprehensive literature search was conducted in PubMed, Scopus, and Web of Science for studies published up to 2026. Both human epidemiological studies and experimental animal models were included to evaluate the effects of maternal obesity on offspring outcomes. Keywords included “maternal obesity”, “offspring health”, “developmental programming”, “metabolic disorders”, “neurodevelopment”, and “immunology”. Relevant studies were critically assessed, with particular focus on mechanisms, sex-specific effects, and long-term consequences. Results / Methodology: Evidence indicates that maternal obesity programs offspring health through multiple pathways, including altered metabolism, epigenetic modifications, inflammatory processes, and microbiome-mediated effects. Offspring of obese mothers exhibit higher risk of hypertension, insulin resistance, type 2 diabetes, dyslipidemia, impaired renal development, neurodevelopmental and behavioral disorders, and immune dysregulation. These effects are often sex-specific and may persist throughout childhood and adulthood. Both preconception and gestational interventions, including weight management and lifestyle optimization, can partially mitigate these risks. Conclusion: Maternal obesity is a major determinant of long-term multisystem health outcomes in offspring. Understanding the mechanisms of developmental programming is essential for developing preventive strategies, emphasizing the importance of maternal health optimization before and during pregnancy.

30 June 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
WSWiktoria Szkatuła
Wiktoria Szkatuła
MSMarcin Krzysztof Schulz
Marcin Krzysztof Schulz
AMAgnieszka Morawa
Agnieszka Morawa
DSDawid Studziński
Dawid Studziński
KOKarolina Osińska
Karolina Osińska
AKAnna Kołcz
Anna Kołcz
Introduction: Hypertrophic cardiomyopathy (HCM) is an inherited condition characterized by sarcomeric hypercontractility, leading to dynamic left ventricular outflow tract (LVOT) obstruction in approximately 70% of patients. Mavacamten, a first-in-class selective cardiac myosin inhibitor, addresses the underlying molecular cause by reducing excessive actin-myosin cross-bridge formation. Aim: To evaluate the clinical efficacy and safety of mavacamten in symptomatic obstructive HCM (oHCM) using data from randomized trials and real-world studies. Methods: A systematic search of PubMed, Embase, and Cochrane Library identified 110 publications. Following predefined criteria, 44 studies were included in the final analysis, including pivotal phase III trials (EXPLORER-HCM, VALOR-HCM) and long-term extensions. Results: Mavacamten demonstrated a significant reduction in LVOT gradients (mean reduction of ~47 mmHg in EXPLORER-HCM) and improved quality of life, with KCCQ-CSS scores increasing by an average of 14.2 points. Between 60% and 80% of patients achieved ≥1 NYHA functional class improvement. In the VALOR-HCM trial, approximately 90% of patients avoided invasive septal reduction therapy (SRT) through 128 weeks. The primary safety concern was a transient reduction in LVEF (<50%) occurring in 5–14% of patients, which was typically reversible with dose titration. Conclusion: Mavacamten is a transformative non-invasive therapy that shifts oHCM management from palliative care to mechanism-targeted treatment. While highly effective in improving hemodynamics and functional capacity, rigorous echocardiographic monitoring remains mandatory to ensure safety regarding systolic function.

17 February 2026 in Quality in Sport
Verified
Journal Article
Open access
KTKonrad Turczynowski
Konrad Turczynowski
JLJakub Lichoń
Jakub Lichoń
PKPaweł Kuna
Paweł Kuna
WKWojciech Kuna
Wojciech Kuna
JPJakub Pietrucha
Jakub Pietrucha
DSDawid Studziński
Dawid Studziński
Background.GLP-1 receptor agonists (GLP-1RAs) are central to obesity pharmacotherapy, producing substantial and sustained weight loss in randomized trials, with additional cardiometabolic benefits. Growing attention concerns their effects on body composition, particularly fat versus lean mass loss, and potential impacts on skeletal muscle function and physical performance. These outcomes are highly relevant to sports medicine and rehabilitation, where muscle preservation is crucial. Aim.To review evidence on the effects of GLP-1RAs on body composition and physical performance in adults with obesity, focusing on fat mass, lean mass and populations at risk of muscle-related adverse effects. Materials and methods.Narrative review of 30 PubMed-indexed studies (2015–2026), including RCTs, DXA substudies and reviews of liraglutide, semaglutide and tirzepatide in adults with overweight/obesity. Results.GLP-1RAs consistently reduced body weight and fat mass, with 15–40% of weight loss attributable to lean mass reduction. Semaglutide improved physical function and exercise tolerance in obesity-related functional impairment and HFpEF, while potential sarcopenic effects were reported in older adults and those with low baseline muscle mass. Reviews highlight heterogeneity of lean mass responses and the importance of lifestyle interventions. Conclusions.GLP-1RAs induce major fat loss but are associated with clinically relevant lean mass loss. Combining pharmacotherapy with exercise and nutrition is essential to optimize body composition and physical performance.

21 December 2025 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
MSMarcin Krzysztof Schulz
Marcin Krzysztof Schulz
MKMichał Kulczak
Michał Kulczak
DSDawid Studziński
Dawid Studziński
AKAnna Kołcz
Anna Kołcz
AMAgnieszka Morawa
Agnieszka Morawa
KOKarolina Osińska
Karolina Osińska
Advanced heart failure (AHF) constitutes a terminal expression of cardiovascular disease, associated with severe, refractory symptoms and high mortality despite optimized medical therapy. Levosimendan, a first-in-class inodilator, addresses this challenge, acting as a calcium sensitizer and potassium channel opener. Its unique tripartite mechanism provides positive inotropy independently of the cAMP pathway, critically avoiding increased intracellular calcium or myocardial oxygen demand. The active metabolite, OR-1896, ensures prolonged hemodynamic benefits lasting up to two weeks, supporting intermittent, outpatient bridging strategies. This systematic literature review synthesized current evidence by applying a rigorous search strategy across biomedical databases, resulting in the inclusion of 32 scientific publications encompassing high-level evidence such as meta-analyses, randomized controlled trials (RCTs), and cohort studies. Pooled analyses suggest that repetitive levosimendan administration significantly improves Left Ventricular Ejection Fraction (LVEF), reduces NT-proBNP levels, and is associated with a reduced risk of all-cause mortality (RR 0.60). Furthermore, it confers vital organoprotective effects, notably improving renal function in patients awaiting heart transplantation (HTx), and its preoperative use as a "bridge to transplant" (BTT) is deemed safe. Despite compelling data from small RCTs (e.g., LION-HEART), the field requires larger, definitive studies—such as the ongoing LEIA-HF trial—to establish the precise role of levosimendan in contemporary AHF management.